National Health (June 2018 Anniversary statutory price reduction) (Exercise of Ministerial discretion) Determination 2018
National Health Act 1953
I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ACF(3) of the National Health Act 1953.
Dated 29 May 2018
LISA LA RANCE
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name of Determination
This instrument is the National Health (June 1 2018 Anniversary statutory price reduction) (Exercise of Ministerial discretion) Determination 2018.
2 Commencement
This instrument commences on the day it is made.
3 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act,
In this instrument:
Act means the National Health Act 1953.
price reduction day has the same meaning as in section 99ACL of the Act.
4 Authority
This instrument is made under subsection 99ACF(3) of the Act.
5 Brand of pharmaceutical item not subject to a price reduction
I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is not reduced under a provision mentioned in item 5 or 6 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the price reduction day.
6 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply
I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 2 is reduced under a provision mentioned in item 5 or 6 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the price reduction day by the percentage specified in column 3 of the table item.
Schedule 1— Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand |
1 | Albendazole | Tablet 200 mg | Oral | Zentel |
2 | Albendazole | Tablet 400 mg | Oral | Eskazole |
3 | Atovaquone | Oral suspension 750 mg per 5 mL, 210 mL | Oral | Wellvone |
4 | Atropine | Injection containing atropine sulfate 600 micrograms in 1 mL | Injection | Pfizer Australia Pty Ltd |
5 | Auranofin | Capsule 3 mg | Oral | Ridaura |
6 | Benztropine | Injection containing benztropine mesylate 2mg in 2 mL | Injection | Benzatropine Injection |
7 | Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig |
8 | Cholestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g cholestyramine), 50 | Oral | Questran Lite |
9 | Cortisone | Tablet containing cortisone acetate 25 mg | Oral | Cortate |
10 | Cortisone | Tablet containing cortisone acetate 5 mg | Oral | Cortate |
11 | Cyclophosphamide | Tablet 50 mg | Oral | Cycloblastin |
12 | Cytarabine | Injection 100 mg in 5 mL vial | Injection | Pfizer Australia Pty Ltd |
13 | Dantrolene | Capsule containing dantrolene sodium 25 mg | Oral | Dantrium |
14 | Dantrolene | Capsule containing dantrolene sodium 50 mg | Oral | Dantrium |
15 | Ethosuximide | Oral solution 250 mg per 5 mL, 200 mL | Oral | Zarontin |
16 | Flupenthixol decanoate | Oily I.M. injection 100 mg in 1 mL ampoule | Injection | Fluanxol Concentrated Depot |
17 | Flupenthixol decanoate | Oily I.M. injection 20 mg in 1 mL | Oral | Foltabs 500 |
18 | Folic acid | Tablet 5 mg | Oral | Megafol 5 |
19 | Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 |
20 | Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 |
21 | Haloperidol | Tablet 5 mg | Oral | Serenace |
22 | Hydromorphone | Injection containing hydromorphone hydrochloride 10 mg in 1 mL | Injection | Dilaudid-HP |
23 | Hydromorphone | Injection containing hydromorphone hydrochloride 2 mg in 1 mL | Injection | Dilaudid |
24 | Hydromorphone | Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 473 mL | Oral | Dilaudid |
25 | Hydromorphone | Tablet containing hydromorphone hydrochloride 2 mg | Oral | Dilaudid |
26 | Hydromorphone | Tablet containing hydromorphone hydrochloride 4 mg | Oral | Dilaudid |
27 | Hydromorphone | Tablet containing hydromorphone hydrochloride 8 mg | Oral | Dilaudid |
28 | Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb |
29 | Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR |
30 | Mercaptopurine | Tablet 50 mg | Oral | Purinethol |
31 | Milk powder -- synthetic | Low calcium oral powder 400 g (Locasol) | Oral | Locasol |
32 | Nitrofurantoin | Capsule 100 mg | Oral | Macrodantin |
33 | Nitrofurantoin | Capsule 50 mg | Oral | Macrodantin |
34 | Phenytoin | Oral suspension 30 mg per 5 mL, 500 mL | Oral | Dilantin |
35 | Pneumococcal vaccine - polyvalent | Injection 0.5 mL (23 valent) | Injection | Pneumovax 23 |
36 | Progesterone | Capsule 200 mg | Vaginal | Utrogestan |
37 | Progesterone | Pessary 100 mg | Vaginal | Oripro |
38 | Progesterone | Pessary 200 mg | Vaginal | Oripro |
39 | Reboxetine | Tablet 4 mg (as mesilate) | Oral | Edronax |
40 | Sirolimus | Oral solution 1 mg per mL, 60 mL | Oral | Rapamune |
41 | Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit |
42 | Triglycerides - medium chain, formula | Oral powder 400 g (Monogen) | Oral | Monogen |
43 | Zuclopenthixol decanoate | Oily I.M. injection 200 mg in 1 mL | Injection | Clopixol Depot |
Schedule 2— Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply
Column 1 | Column 2 | Column 3 | |||
Item | Brand of pharmaceutical item | Percentage | |||
| Drug | Form | Manner of administration | Brand |
|
1 | Amphotericin | Lozenge 10 mg | Oral | Fungilin | 8.12% |
2 | Benzathine Benzylpenicillin | Injection 900 mg in 2.3 mL single use pre-filled syringe | Injection | Bicillin L-A | 3.6% |
3 | Benzylpenicillin | Powder for injection 3 g (as sodium) | Injection | BenPen | 7.28% |
4 | Benzylpenicillin | Powder for injection 600 mg (as sodium) | Injection | BenPen | 7.54% |
5 | Chlorambucil | Tablet 2 mg | Oral | Leukeran | 10.83% |
6 | Diphtheria and tetanus vaccine, adsorbed, diluted for adult use | Injection 0.5 mL in pre-filled syringe | Injection | ADT Booster | 5.89% |
7 | Ethosuximide | Capsule 250 mg | Oral | Zarontin | 9.50% |
8 | Glucagon | Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe | Injection | GlucaGen Hypokit | 5.61% |
9 | Haloperidol | Oral solution 2 mg per mL, 100 mL | Oral | Serenace | 9.28% |
10 | Haloperidol | Tablet 1.5 mg | Oral | Serenace | 1.16% |
11 | Haloperidol | Tablet 500 micrograms | Oral | Serenace | 3.77% |
12 | Heparin | Injection (preservative-free) 5,000 I.U. (as sodium) in 5 mL | Injection | Pfizer Australia Pty Ltd | 0.61% |
13 | Heparin | Injection 5,000 units (as sodium) in 0.2 mL | Injection | Hospira Pty Limited | 2.72% |
14 | Lignocaine | Injection containing lignocaine hydrochloride 50 mg in 5 mL | Injection | Pfizer Australia Pty Ltd | 1.95% |
15 | Nafarelin | Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses | Nasal | Synarel | 3.21% |
16 | Nystatin | Capsule 500,000 units | Oral | Nilstat | 3.94% |
17 | Nystatin | Tablet 500,000 units | Oral | Nilstat | 3.94% |
18 | Oestriol | Pessaries 500 micrograms, 15 | Vaginal | Ovestin Ovula | 12.75% |
19 | Oestriol | Vaginal cream 1 mg per g, 15 g | Application | Ovestin | 5.81% |
20 | Warfarin | Tablet containing warfarin sodium 1 mg | Oral | Coumadin | 5.64% |
21 | Warfarin | Tablet containing warfarin sodium 1 mg | Oral | Marevan | 5.64% |
22 | Warfarin | Tablet containing warfarin sodium 2 mg | Oral | Coumadin | 6.98% |
23 | Warfarin | Tablet containing warfarin sodium 3 mg | Oral | Marevan | 4.77% |